BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2013-10-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-12-0993-TPMID 24170767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

  2011cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

  2011cited by this paper
• A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

  2011cited by this paper
• Cancer Therapy : Preclinical The Selective Class I PI 3 K Inhibitor CH 5132799 Targets Human Cancers Harboring Oncogenic PIK 3 CA Mutations

  2011cited by this paper
• BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

  2011cited by this paper
• AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

  2011cited by this paper
• Abstract 3833: Molecular mechanisms by which BAY 80-6946 induces apoptosis in breast tumor cells as single agent or in combination

  2011cited by this paper
• A beta version of life: p110β takes center stage

  2010cited by this paper
• Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

  2010cited by this paper
• Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

  2010cited by this paper
• PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control.

  2010cited by this paper
• Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.

  2010cited by this paper
• MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

  2010cited by this paper
• Phosphatidylinositol 3-kinase: the oncoprotein.

  2010cited by this paper
• Targeting the PI3K signaling pathway in cancer.

  2010cited by this paper
• Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

  2009cited by this paper
• PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

  2009cited by this paper
• Should individual PI3 kinase isoforms be targeted in cancer?

  2009cited by this paper
• PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients

  2009cited by this paper
• Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

  2008cited by this paper
• PTEN-deficient cancers depend on PIK3CB

  2008cited by this paper
• Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

  2008cited by this paper
• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  2008influential reference
• Class I PI3K in oncogenic cellular transformation

  2008cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Targeting HER proteins in cancer therapy and the role of the non-target HER3

  2007cited by this paper
• Regulation of class IA PI3Ks.

  2007cited by this paper
• Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.

  2005cited by this paper
• Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis

  2005cited by this paper
• Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.

  2005cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• PI3K-Akt pathway: Its functions and alterations in human cancer

  2004cited by this paper
• The p85 Regulatory Subunit Controls Sequential Activation of Phosphoinositide 3-Kinase by Tyr Kinases and Ras*

  2002cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper

• Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

  2026cites this paper
• Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors

  2025cites this paper
• Early phase development of PI3kinase inhibitors for anticancer therapies

  2025cites this paper
• Research Progress on Drugs Targeting PIK3CA Mutations

  2025cites this paper
• Phosphatidylinositol-4,5-bisphosphate 3-kinase family in GtoPdb v.2025.1

  2025cites this paper
• Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma.

  2025cites this paper
• Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study

  2025cites this paper
• Phosphoinositide-3-kinase δ as an immune check-pathway in cancer Immunology. Therapeutic prospects

  2025cites this paper
• Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.

  2025cites this paper
• Deficiency in N-cadherin-Akt3 signaling impairs the blood-brain barrier

  2025cites this paper
• Cancer-Associated PIK3R1 Genetic Aberrations and Precision Medicine

  2025cites this paper
• Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids

  2025cites this paper
• Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

  2025cites this paper
• Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer.

  2025cites this paper
• Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells

  2025cites this paper
• Geranylgeranyl transferase‐1 inhibitor GGTI‐2417 enhances the anti‐tumour efficacy of histone deacetylase inhibitors in different T‐cell lymphoma lines

  2025cites this paper
• Phosphatidylinositol kinases in GtoPdb v.2025.1

  2025cites this paper
• Small molecule inhibitors for treating breast cancer: drug analysis based on the pathogenesis of breast cancer.

  2025cites this paper
• LEVELS OF GENE EXPRESSION FOR LAD1 AND EGFR IN PATIENTS WITH LARYNGEAL CANCER

  2025cites this paper
• Beyond Atrial Fibrillation and Heart Failure: Ibrutinib-induced Pericardial Effusion

  2025cites this paper
• Unveiling the Role of PIK3R1 in Cancer: A Comprehensive Review of Regulatory Signaling and Therapeutic Implications.

  2024cites this paper
• Unveiling FDA-Approved Drugs and Formulations in the Management of Bladder Cancer: A Review.

  2024cites this paper
• The Importance of Phosphoinositide 3-Kinase in Neuroinflammation

  2024cites this paper
• The Role of PTEN in Chemoresistance Mediated by the HIF-1α/YY1 Axis in Pediatric Acute Lymphoblastic Leukemia

  2024cites this paper
• Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions

  2024cites this paper
• MVGNet: Prediction of PI3K Inhibitors Using Multitask Learning and Multiview Frameworks

  2024cites this paper
• β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models

  2024cites this paper
• Tumor biomarkers for diagnosis, prognosis and targeted therapy

  2024cites this paper
• Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen

  2024cites this paper
• Chronic Inflammation and Cancer: Key Pathways and Targeted Therapies

  2024cites this paper
• Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

  2024cites this paper
• p53 Orchestrates Cancer Metabolism: Unveiling Strategies to Reverse the Warburg Effect

  2024cites this paper
• PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.

  2024cites this paper
• PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.

  2024cites this paper
• Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

  2024cites this paper
• Emerging molecular therapies in the treatment of bladder cancer

  2024cites this paper
• Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.

  2024cites this paper
• Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ‐B3525 in Chinese patients with advanced cancers

  2024cites this paper
• Anticancer Drug Discovery from Natural Compounds Targeting PI3K/AKT/mTOR Signaling Pathway.

  2024cites this paper
• Exploring the antiproliferative and proapoptotic activities of new pyridopyrimidine derivatives and their analogs.

  2024cites this paper
• Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer

  2024cites this paper
• PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment

  2024cites this paper
• B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia

  2024cites this paper
• PI3K inhibitors in hematology: When one door closes….

  2024cites this paper
• PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.

  2023cites this paper
• Synthetic methodologies and SAR of quinazoline derivatives as PI3K inhibitors.

  2023cites this paper
• Potential therapeutic molecular targets for better outcomes for patients with lung cancer

  2023cites this paper
• Phosphatidylinositol kinases in GtoPdb v.2023.1

  2023cites this paper
• Aging - what it is and how to measure it.

  2023cites this paper
• Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.

  2023cites this paper
• The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

  2023cites this paper
• Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

  2023cites this paper
• Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

  2023cites this paper
• Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

  2023cites this paper
• Leveraging molecular structure and bioactivity with chemical language models for de novo drug design

  2023influential citation
• PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications

  2023cites this paper
• Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer

  2023cites this paper
• Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses

  2023cites this paper
• Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention

  2023cites this paper
• Synthesis and application of small molecules approved for the treatment of lymphoma.

  2023cites this paper
• The effects of ARID1A mutation in gastric cancer and its significance for treatment

  2023cites this paper
• Evaluation of the anti-inflammatory effects of PI3Kδ/γ inhibitors for treating acute lung injury.

  2023cites this paper
• Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

  2023cites this paper
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

  2023cites this paper
• Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

  2023cites this paper
• Discovery of a Photosensitizing PI3K Inhibitor for Tumor Therapy: Design, Synthesis and in vitro Biological Evaluation.

  2023cites this paper
• Phosphatidylinositol-4,5-bisphosphate 3-kinase family in GtoPdb v.2023.1

  2023cites this paper
• Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.

  2023cites this paper
• Cardiotoxicity of BTK inhibitors: ibrutinib and beyond

  2022cites this paper
• Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

  2022cites this paper
• Risks and management of hypertension in cancer patients undergoing targeted therapy: a review

  2022cites this paper
• A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma

  2022cites this paper
• Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling.

  2022cites this paper
• PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment

  2022cites this paper
• Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy

  2022cites this paper
• Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma

  2022cites this paper
• Upregulation of PIK3IP1 monitors the anti-cancer activity of PI3Kα inhibitors in gastric cancer cells.

  2022cites this paper
• Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

  2022cites this paper
• Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma

  2022cites this paper
• Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials

  2022cites this paper
• Beyond PI3Ks: targeting phosphoinositide kinases in disease

  2022cites this paper
• PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?

  2022influential citation
• Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

  2022cites this paper
• Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

  2022cites this paper
• PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

  2022cites this paper
• Validated LC-MS/MS method for the determination of copanlisib in mouse dried blood spots.

  2022cites this paper
• Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

  2022cites this paper
• Targeting the “hallmarks of aging” to slow aging and treat age-related disease: fact or fiction?

  2022cites this paper
• Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

  2022cites this paper
• Development of PI3K inhibitors: advances in clinical trials and new strategies (Review).

  2021cites this paper
• Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib

  2021cites this paper
• Специфични аспекти в проучването на онкогенезата и метастазирането на ларингеален плоскоклетъчен карцином

  2021cites this paper
• PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

  2021cites this paper
• Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.

  2021cites this paper
• Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse

  2021cites this paper
• Breast Cancer Treatments: Updates and New Challenges

  2021cites this paper
• Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2021cites this paper
• EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.

  2021cites this paper
• Copanlisib in non-Hodgkin's lymphoma and solid tumors: An efficacy and safety analysis

  2021influential citation
• Current status and future perspective of immune checkpoint inhibitors in colorectal cancer.

  2021cites this paper